295 related articles for article (PubMed ID: 32414185)
1. ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy.
Vitale MG; Barbato C; Crispo A; Habetswallner F; Martino BM; Riccardi F; Maione A; Eisenwagen S; Vitale G; Cartenì G
Molecules; 2020 May; 25(10):. PubMed ID: 32414185
[TBL] [Abstract][Full Text] [Related]
2. Survival analyses of the ZeOxaNMulti trial: Follow-up randomized, double-blinded, placebo-controlled trial of oral PMA-zeolite to prevent chemotherapy-induced side effects, especially peripheral neuropathy.
Vitale MG; Crispo A; Arundine D; Ronga R; Barbato C; Luongo A; Habetswallner F; De Martino BM; Maione A; Eisenwagen S; Vitale G; Riccardi F
Front Pharmacol; 2022; 13():874028. PubMed ID: 36425572
[TBL] [Abstract][Full Text] [Related]
3. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
4. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
5. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Leal AD; Qin R; Atherton PJ; Haluska P; Behrens RJ; Tiber CH; Watanaboonyakhet P; Weiss M; Adams PT; Dockter TJ; Loprinzi CL;
Cancer; 2014 Jun; 120(12):1890-7. PubMed ID: 24619793
[TBL] [Abstract][Full Text] [Related]
6. Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study.
Cohen SA; Veleber S; Siman J; Guthrie KA; McMillen K; Heit M; Wadhera S; Daniels J; Hansen K; Jacoby M; Taromina K; Chin S; Romeo M; Langley BO; Coveler AL; Hannan LM; King G; Purcell T; Safyan RA; Shankaran V; Zhen DB; Chiorean EG; Greenlee H
Contemp Clin Trials; 2023 Aug; 131():107273. PubMed ID: 37380021
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
8. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
9. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
12. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
14. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx
Glimelius B; Manojlovic N; Pfeiffer P; Mosidze B; Kurteva G; Karlberg M; Mahalingam D; Buhl Jensen P; Kowalski J; Bengtson M; Nittve M; Näsström J
Acta Oncol; 2018 Mar; 57(3):393-402. PubMed ID: 29140155
[TBL] [Abstract][Full Text] [Related]
15. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: A mediation effect analysis.
Lu LC; Tsay SL; Chang SY; Chen CM; Liu CY
Cancer Med; 2019 Mar; 8(3):963-971. PubMed ID: 30741481
[TBL] [Abstract][Full Text] [Related]
16. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment of chemotherapy-induced peripheral neuropathy.
Piccolo J; Kolesar JM
Am J Health Syst Pharm; 2014 Jan; 71(1):19-25. PubMed ID: 24352178
[TBL] [Abstract][Full Text] [Related]
18. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
Wu S; Bai X; Guo C; Huang Z; Ouyang H; Huang J; Zeng W
BMC Cancer; 2021 Nov; 21(1):1173. PubMed ID: 34727879
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
[TBL] [Abstract][Full Text] [Related]
20. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]